In short
Clinical trials are investigating ATIGOTATUG in people with extensive-stage small cell lung cancer. The study is checking whether ATIGOTATUG, given with other treatment, helps people live longer than the current comparison treatment. It is a Phase 3 trial focused on first-line therapy.
Key points
- ATIGOTATUG is being studied in a Phase 3 clinical trial for people with extensive-stage small cell lung cancer. The trial looks at ATIGOTATUG in a fixed-dose combination with nivolumab, given with chemotherapy, and compares it with atezolizumab plus chemotherapy. The study is testing first-line treatment, so it is meant for initial therapy after diagnosis. The main endpoint is overall survival, which means how long participants live after joining the study. The planned enrollment is 530 participants. The trial status is listed as Authorised.
Trial overview
The clinical trial with ID NCT06646276 is studying ATIGOTATUG in people with extensive-stage small cell lung cancer (ES-SCLC). The trial is authorised and planned as a Phase 3 study with 530 participants.
This study is testing ATIGOTATUG as part of a fixed-dose combination with nivolumab, given together with chemotherapy, and comparing it with atezolizumab plus chemotherapy. The study is focused on first-line therapy, which means the first main treatment used for the cancer.
Who is being studied
The target population is participants with extensive-stage small cell lung cancer. This means the trial is not for all lung cancers, but for this specific advanced form of small cell lung cancer.
The study is looking at people who are starting treatment, because it is designed as first-line therapy research. In simple terms, the trial is asking whether this treatment approach works well as the first treatment option.
Treatments being compared
One study group receives ATIGOTATUG in a fixed-dose combination with nivolumab, along with chemotherapy medicines. The chemotherapy drugs listed in the trial are etoposide and carboplatin.
The comparison group receives atezolizumab with chemotherapy. This head-to-head comparison helps researchers see whether the ATIGOTATUG-containing approach may offer better results than the current comparator treatment.
Study design and phase
This is an interventional study, which means researchers assign treatments and then measure the results. It is also a Phase 3 trial, which is usually done in a larger group to compare treatments and confirm benefits.
The planned enrollment is 530 people. That number shows the study is designed to include a fairly large group so the results can be compared across treatment groups.
Main endpoint
The main endpoint is overall survival. Overall survival means how long participants live after entering the study, starting from randomization, which is when people are assigned to a treatment group by chance.
This endpoint matters because it shows whether one treatment approach helps people live longer than the other. In this trial, that is the main way researchers will judge the treatment benefit.
What this may mean for patients
For patients, this trial is testing whether a new treatment plan that includes ATIGOTATUG can improve outcomes when used at the start of care for ES-SCLC. The study does not describe long-term results yet, so it is still focused on learning whether the new approach is better than the comparison treatment.
Because it is a Phase 3 trial, the study is part of the later stages of clinical research. The main question is simple: does the ATIGOTATUG-containing treatment help people live longer than atezolizumab with chemotherapy?